Estimation of the number of inherited prion disease mutation carriers in the UK.
Journal
European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
25
03
2022
accepted:
09
06
2022
revised:
26
05
2022
pubmed:
27
6
2022
medline:
14
10
2022
entrez:
26
6
2022
Statut:
ppublish
Résumé
Inherited prion diseases (IPD) are a set of rare neurodegenerative diseases that are always caused by mutation of the prion protein gene (PRNP). These are highly heterogeneous in clinical presentation and best described by the specific gene mutation, but traditionally include the canonical syndromes familial Creutzfeldt-Jakob disease, Gerstamann-Straussler-Scheinker syndrome, and fatal familial insomnia. In the UK, care of IPD patients and clinical PRNP sequencing have been carried out almost exclusively by the National Prion Clinic and affiliated laboratories since the disease gene was discovered in 1989. Using data obtained over 30 years (1990-2019), this study aimed to provide a greater understanding of the genetic prevalence of IPD using multiple complementary methods. A key source of bias in rare disorders is ascertainment, so we included an analysis based on capture-recapture techniques that may help to minimise ascertainment bias. 225 patients, with 21 different IPD mutations were identified, varying in frequency (with 8/21 mutations comprising over 90% observed cases), derived from 116 kindreds and 151 3-generation families. We estimated a total of 303 UK families (95% CI = 222, 384) segregate IPD mutations, 1091 (95% CI = 720, 1461) UK mutation carriers and a lifetime risk of approximately 1 in 60,000. Simpler methods of measuring prevalence based on extrapolation from the annual incidence of disease, and large scale genomic studies, result in similar estimates of prevalence. These estimates may be of value for planning preventive trials of therapeutics in IPD mutation carriers, prevention of prion disease transmission and provision of specialist services.
Identifiants
pubmed: 35754056
doi: 10.1038/s41431-022-01132-8
pii: 10.1038/s41431-022-01132-8
pmc: PMC9553982
doi:
Substances chimiques
Prion Proteins
0
Prions
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1167-1170Subventions
Organisme : Medical Research Council
ID : G0400713
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00024/9
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
Lancet Neurol. 2020 Apr;19(4):361-368
pubmed: 32199098
Brain. 2006 Sep;129(Pt 9):2297-317
pubmed: 16923955
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Nature. 2015 Jun 25;522(7557):478-81
pubmed: 26061765
Am J Alzheimers Dis Other Demen. 2015 Dec;30(8):752-5
pubmed: 26320231
Nat Rev Neurol. 2021 Jan;17(1):23-36
pubmed: 33168964
Hum Mutat. 2010 Jul;31(7):E1551-63
pubmed: 20583301
Brain. 2008 Oct;131(Pt 10):2632-46
pubmed: 18757886
Mol Psychiatry. 2020 Dec;25(12):3399-3412
pubmed: 30279455
Lancet Neurol. 2020 Oct;19(10):840-848
pubmed: 32949544
N Engl J Med. 2009 Nov 19;361(21):2056-65
pubmed: 19923577
Sci Transl Med. 2016 Jan 20;8(322):322ra9
pubmed: 26791950
Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2710-2716
pubmed: 31964843
Lancet Neurol. 2022 Apr;21(4):342-354
pubmed: 35305340
Lancet Neurol. 2022 Mar;21(3):234-245
pubmed: 35182509
BMJ Open. 2014 May 16;4(5):e004968
pubmed: 24838726
Ann Neurol. 1998 Jun;43(6):826-8
pubmed: 9629853
Annu Rev Genet. 2019 Dec 3;53:117-147
pubmed: 31537104
Fam Cancer. 2019 Jan;18(1):67-73
pubmed: 30019097